Transfer of value disclosure

The disclosure of payments to healthcare professionals (HCPs) and healthcare organisations (HCOs) is about bringing further transparency to the relationship between industry and the people it works with.  It is a relationship that is critical to the future of medical innovation and patient care and as such, should meet the high expectations of patients and wider stakeholders.

The Association of British Pharmaceutical Industry (ABPI) Code of Practice requires all pharmaceutical companies to annually disclose payments and benefits in kind – known as transfers of value – made to UK HCPs and HCOs.

 

Actelion Pharmaceuticals UK Ltd is committed to ensuring transparency of its relationships with HCPs and HCOs by operating within the ABPI Code of Practice for the UK pharmaceutical industry, the Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the Irish pharmaceutical industry and the Prescription Medicines Code of Practice Authority (PMCPA).

Since 2015, our transfers of value to HCPs and HCOs have been submitted to the ABPI disclosure database, where disclosure information is published annually. 

 

To view Actelion’s transfers of value data from 2015, and for more information on the Disclosure initiative, visit the ABPI Disclosure UK website at www.disclosureuk.org.uk

 

The following payments were made to HCPs and HCOs by Actelion Pharmaceuticals UK Ltd in 2014: